2021
A reply to “Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC”
Jairam V, Soulos PR, Gross CP, Yu JB, Park HS, Decker RH. A reply to “Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC”. Lung Cancer 2021, 168: 84-85. PMID: 34933760, DOI: 10.1016/j.lungcan.2021.12.003.Peer-Reviewed Case Reports and Technical NotesPan‐cancer analysis of prognostic metastatic phenotypes
Zaorsky NG, Wang X, Garrett SM, Lehrer EJ, Lin C, DeGraff DJ, Spratt DE, Trifiletti DM, Kishan AU, Showalter TN, Park HS, Yang JT, Chinchilli VM, Wang M. Pan‐cancer analysis of prognostic metastatic phenotypes. International Journal Of Cancer 2021, 150: 132-141. PMID: 34287840, PMCID: PMC8595638, DOI: 10.1002/ijc.33744.Peer-Reviewed Original ResearchConceptsLiver/lung metastasisLung metastasesOverall survivalMetastatic cancerConcordance indexCancer stage IV diseaseCox proportional hazards modelMetastatic phenotypeNational Cancer DatabaseStage IV diseaseEnd Results (SEER) databaseAmerican Joint CommitteeLong-term survivorsLatent class analysisProportional hazards modelStage IVANomogram modelResults databaseSurvival outcomesBetter prognosticationCancer DatabasePan-cancer analysisClinical trialsHazards modelJoint CommitteeFinancial relationships between industry and principal investigators of US cooperative group randomized cancer clinical trials
Metzger AL, Appiah A, Wright CM, Jairam V, Amini A, Park HS, Welsh JW, Thomas CR, Verma V, Ludmir EB. Financial relationships between industry and principal investigators of US cooperative group randomized cancer clinical trials. International Journal Of Cancer 2021, 149: 1683-1690. PMID: 34173669, DOI: 10.1002/ijc.33719.Peer-Reviewed Original ResearchConceptsClinical trialsMultivariable gamma regression analysesNational Clinical Trials NetworkPrincipal investigatorPhase III componentSystemic therapy trialsUS cooperative groupsClinical Trials NetworkCooperative groupsCancer clinical trialsGamma regression analysisSystemic therapySuch RCTsTherapy trialsRCTsTrials NetworkTrialsRegression analysisOne-thirdMedical journalsDrugsCombinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review
Hayman TJ, Bhatia AK, Jethwa KR, Young MR, Park HS. Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review. Translational Cancer Research 2021, 10: 2571-2585. PMID: 35116571, PMCID: PMC8798834, DOI: 10.21037/tcr-20-2096.Peer-Reviewed Original ResearchNeck squamous cell carcinomaSquamous cell carcinomaRadiation therapyCell carcinomaImmune responseNon-surgical treatment modalitiesCell death ligand 1Cell death protein 1Cancer-directed therapyCombination of immunotherapyAnti-tumor responseDeath ligand 1Death protein 1Adaptive immune responsesAdaptive immune systemAdvanced HNSCCAdvanced diseaseMetastatic settingPostoperative settingSystemic therapyImmunomodulatory effectsTreatment modalitiesRecurrent/Clinical trialsClinical data
2019
Results of a pilot/phase II study of gamma knife radiosurgery for brain metastases and implications for future prospective clinical trials
Yu J, Singh C, Bindra R, Contessa J, Husain Z, Hansen J, Park H, Roberts K, Bond J, Tien C, Guo F, Colaco R, Housri N, Magnuson W, Mahajan A, Omay S, Chiang V. Results of a pilot/phase II study of gamma knife radiosurgery for brain metastases and implications for future prospective clinical trials. Journal Of Radiation Oncology 2019, 8: 39-46. DOI: 10.1007/s13566-018-0370-7.Peer-Reviewed Original ResearchYale-New Haven HospitalPhase II studyBrain metastasesClinical trialsII studyKnife radiosurgeryLocal controlPre-defined primary endpointWhole-brain radiation treatmentFuture prospective clinical trialsEvaluable brain metastasesSymptomatic radiation necrosisMedian patient ageLocal control ratePhase 2 studyGood local controlProspective clinical trialsNumber of metastasesLarge clinical trialsProportional hazards regressionFuture clinical trialsGamma knife radiosurgeryImportant clinical variablesStandard clinical practiceNew Haven HospitalIs Proton Therapy a “Pro” for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database
Chowdhary M, Lee A, Gao S, Wang D, Barry PN, Diaz R, Bagadiya NR, Park HS, Yu JB, Wilson LD, Moran MS, Higgins SA, Knowlton CA, Patel KR. Is Proton Therapy a “Pro” for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database. Frontiers In Oncology 2019, 8: 678. PMID: 30693271, PMCID: PMC6339938, DOI: 10.3389/fonc.2018.00678.Peer-Reviewed Original ResearchLymph node irradiationNational Cancer DatabaseOverall survivalMultivariable analysisBreast cancerCancer DatabaseProton radiotherapyNon-metastatic breast cancerCox proportional hazards modelHigher heart dosesN2-N3 diseaseMultivariate logistic analysisProportional hazards modelAcademic facilitiesLogistic regression modelsHeart dosesAdjuvant radiotherapyNode irradiationHazard ratioNode positivityClinical benefitClinical trialsPRT patientsStage 0Hazards model